Clinical trials and therapy.
Parallel-group studies have established the efficacy of cholinesterase inhibitors in Alzheimer's disease, at least for short-term cognitive and clinical global enhancement. Noncognitive outcomes are currently under scrutiny. Time to reach clinical milestones may be a more useful trial design for new studies aiming to delay appearance or progression of disease.